Let’s discuss the FDA's new approach to including diverse patient populations in oncology clinical trials. It emphasizes the importance of diversity in research for developing effective cancer treatments, addressing health disparities, and advancing personalized medicine. The document highlights challenges such as overcoming mistrust and logistical barriers in underrepresented communities and underscores the FDA's commitment to healthcare equity.